Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disease progression08.01.03.0380.001250%
Drug intolerance08.06.01.013--Not Available
Occult blood13.05.02.003--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.0100.003124%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.001250%Not Available
Ulcerative keratitis06.04.02.004; 10.02.01.021--
Cytopenia01.03.03.012--Not Available
Treatment failure08.06.01.0170.003374%Not Available
Skin mass23.07.04.014--Not Available
Anorectal discomfort07.03.03.003--Not Available
Fasting26.01.02.001--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001875%Not Available
Candida infection11.03.03.021--
Excessive cerumen production04.01.01.004--Not Available
Liver function test increased13.03.04.031--Not Available
Malignant melanoma in situ23.08.01.004; 16.03.01.0040.001250%Not Available
Diabetic foot24.04.03.015; 23.07.03.008; 17.09.04.006; 14.07.06.001; 05.07.06.001--Not Available
Skin plaque23.03.03.044--Not Available
Toxic goitre14.11.01.046; 05.02.02.0060.001250%Not Available
Burning feet syndrome23.06.05.010; 17.02.06.038; 15.03.04.019--Not Available
Cutaneous T-cell lymphoma16.17.03.002; 01.11.03.002; 23.07.04.0290.001875%Not Available
Differentiation syndrome22.02.01.036; 16.32.03.037; 12.03.01.063; 08.01.07.0160.003124%Not Available
Diffuse idiopathic skeletal hyperostosis15.01.09.0060.001250%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.001875%Not Available
Idiopathic intracranial hypertension17.07.02.0110.001250%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.001250%Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
Therapeutic product effect incomplete08.06.01.0520.003124%Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene